SLC5A2 and diabetic kidney disease: In human subjects affected by diabetic nephropathy, the expression of SGLT2 mRNA and protein is increased in renal biopsies; moreover, in db/db mice, SGLT2 inhibition modulates renal lipid metabolism and inflammation, counteracting the development of nephropathy [88].